Interestingly, in some studies on adult T-cell leukemia/lymphoma (ATLL), nivolumab appears to increase leukemia progression (NCT02631746) [95,96], indicating that in this disease, PD-1 plays a tumor-suppressive role. The gene discussed is PDCD1; the disease is adult T-cell leukemia/lymphoma.